Tagged with

Gedeon Richter Gedeon Richter’s Erik Bogsch discusses the company’s 100th anniversary, it’s growing international footprint and the future of Hungarian pharma.   Gedeon Richter is known to be the flagship pharmaceutical company in Hungary, and can proudly celebrate its 110th birthday this year. How would you describe Gedeon Richter to our readers?…

Novo Nordisk Hungary We understand that you have been with Novo Nordisk for quite a while already. In the past decade, you also did not sit still in terms of location, working in different international contexts. Can you give our readers some background on the market environment when you first started heading the…

Gedeon Richter Since establishing Gedeon Richter’s operations here 16 years ago, you’ve been involved in the full array of the pharmaceutical spectrum, from R&D, sourcing API, sales and marketing of finished products, and joint ventures with local companies. To begin, would you introduce the company’s China operations to our readers? First off,…

AstraZeneca Serbia As the 7th largest pharma MNC worldwide, AstraZeneca is a company that needs no introduction. However, our readers would love to hear more about your operations here in Serbia… Therefore, can you please first provide them with an idea of the key milestones for the company in Serbia, since you…

Lundbeck Russia Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of this niche is relatively small in Russia, when compared to Western Europe and other developed regions. In Russia, we are…

Materia Medica Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has the organization further developed? We have continued developing quite quicly. In the last few years, the company’s growth was 15–20%…

Lupin Pharmaceuticals Inc. Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with this performance, and were you expecting such strong results? We were pleased, but not very pleased. We thought that we could have done much…

AKRIKHIN You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then, from 2007 to 2010, the company has more than tripled its turnover. It is now one of the top five…

Astellas Russia When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for the rest of the European business to keep up with. All eyes are on you. Do you feel the envy…

Janssen Serbia How does Janssen view the Serbian market today, and how has company built up its presence here in the country? Previously we were working through distribution channels and in 2003 we started to operate as a part of Johnson & Johnson in Serbia. As you know J&J has three parts:…

NATCO Pharma Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game for local players? The Indian market structure is shaped in such way that no generic player gets big market shares.…

Novo Nordisk (Serbia) Novo Nordisk has a long history in Serbia compared to many of the other multinational companies present in the country today. The separate entity Novo Nordisk d.o.o was founded in 2006, but you have been present in the market for over 20 years. Given this history, how would you describe…